Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

INTRODUCTION: AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability profile in a Phase I study of Western patients with solid tumors. This study was conducted to evaluate the safety, pharmacokinetic (PK) profile, maximum tolerated dose (MTD) and efficacy of AZD4877...

Descripción completa

Detalles Bibliográficos
Autores principales: Esaki, Taito, Seto, Takashi, Ariyama, Hiroshi, Arita, Shuji, Fujimoto, Chinatsu, Tsukasa, Koichiro, Kometani, Takuro, Nosaki, Kaname, Hirai, Fumihiko, Yagawa, Katsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130141/
https://www.ncbi.nlm.nih.gov/pubmed/21765863
http://dx.doi.org/10.1111/j.1753-5174.2011.00034.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130141/
https://www.ncbi.nlm.nih.gov/pubmed/21765863
http://dx.doi.org/10.1111/j.1753-5174.2011.00034.x

Ejemplares similares